Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Synergetic regulation of osteoimmune microenvironment and osteogenesis by decellularized amnion membrane for guided bone regeneration

Zhang T., Shao M., Chen X., Zhang R., Zhang B., Wang Y.

Animal Study on Immune Modulation, published in Mater Today Bio (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mater Today Bio (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41445783
PMCID
PMC12723382
DOI
10.1016/j.mtbio.2025.102640
Citations
2

Abstract (original English)

Immunoregulatory properties of guided bone regeneration (GBR) membranes are essential for modulating the osteoimmune microenvironment to enhance osteogenesis. Decellularized amnion membrane (DAM), an extracellular matrix material derived from the placenta through the removal of cells and antigenic components, has attracted attention due to its low immunogenicity and rich composition. This study investigated the role of DAM in modulating the immune microenvironment, its impact on osteogenesis, and associated mechanisms during the GBR process. DAM exhibited high biocompatibility and directly promoted osteogenesis in vitro. Furthermore, DAM induced macrophage M2 polarization, mitigated oxidative stress under inflammatory contexts, and optimized the immune microenvironment, thereby indirectly enhancing cell migration and osteogenic differentiation. Multi-omics analysis revealed a crucial role of the PI3K-Akt signaling pathway, coordinated with immune-related TLR and TNF signaling pathways, in this process-highlighting the potential applications of DAM in the treatment of inflammatory bone defects. DAM's abundant bioactive components and distinctive three-dimensional architecture enable this synergistic effect. In vivo, DAM effectively inhibited inflammation and accelerated bone regeneration in a rat model of critical-size cranial defects. This study demonstrates that DAM possesses

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research